Am­gen's promis­ing gas­tric can­cer drug makes good on Five Prime po­ten­tial with FDA's break­through nod

When Five Prime — now part of Amgen — rolled out mid-stage data for gastric cancer candidate bemarituzumab late last year, it looked like a big win with one major catch: The drug missed its OS primary endpoint. Even still, there was enough promise for Amgen to jump aboard, and apparently, the FDA is interested, too.